Contemporary management of breast cancer in Nigeria: Insights from an institutional database
| Autor: | Anya Romanoff, Oluwole O. Odujoko, Abdul-Rasheed K. Adesunkanmi, Omoniyi-Esan Go, Jeremy Constable, Olusegun I. Alatise, Oladejo O. Lawal, Emmanuella Onabanjo, Olalekan Olasehinde, Akinbolaji A. Akinkuolie, Olukayode Arowolo, Gregory C. Knapp, Idowu Omisile, T.P. Kingham, O C Famurewa, Adewale O. Adisa, Funmilola Wuraola, Adeleye D. Omisore |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Cancer Research Databases Factual Receptor ErbB-2 medicine.medical_treatment Psychological intervention Nigeria Estrogen receptor Breast Neoplasms Disease computer.software_genre Article Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Drug Therapy medicine Humans In patient Prospective Studies Mastectomy Aged Neoplasm Staging Chemotherapy Radiotherapy Database business.industry Disease Management Cancer Middle Aged medicine.disease Survival Analysis Radiation therapy Receptors Estrogen Oncology 030220 oncology & carcinogenesis Female business computer |
| Zdroj: | Int J Cancer |
| ISSN: | 1097-0215 0020-7136 |
| DOI: | 10.1002/ijc.33484 |
| Popis: | High-quality data are needed to guide interventions aimed at improving breast cancer outcomes in sub-Saharan Africa. We present data from an institutional breast cancer database to create a framework for cancer policy and development in Nigeria. An institutional database was queried for consecutive patients diagnosed with breast cancer between January 2010 and December 2018. Sociodemographic, diagnostic, histopathologic, treatment and outcome variables were analyzed. Of 607 patients, there were 597 females with a mean age of 49.8 ± 12.2 years. Most patients presented with a palpable mass (97%) and advanced disease (80.2% ≥ Stage III). Immunohistochemistry was performed on 21.6% (131/607) of specimens. Forty percent were estrogen receptor positive, 32.8% were positive for HER-2 and 43.5% were triple negative. Surgery was performed on 49.9% (303/607) of patients, while 72% received chemotherapy and 7.9% had radiotherapy. At a median follow-up period of 20.5 months, the overall survival was 43.6% (95% CI -37.7 to 49.5). Among patients with resectable disease, 18.8% (57/303) experienced a recurrence. Survival was significantly better for early-stage disease (I and II) compared to late-stage disease (III or IV) (78.6% vs 33.3%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text